Judgement, not just intervention.

A woman presented with a month of distortion in the left eye. That symptomatic eye showed an active macular neovascular membrane and was treated with anti-VEGF therapy. The right eye was asymptomatic, showing only an irregular pigment epithelial detachment with no exudative signs on structural OCT.

On OCT-angiography, however, a well-formed but quiescent (non-exudative) neovascular network was visible in that quiet fellow eye — a membrane present, but not yet leaking. This is a lesion that structural imaging alone will not reveal.

A man in his early fifties had a peripapillary neovascular membrane on a background of pachychoroid and was treated with a course of intravitreal anti-VEGF. Across follow-up the anatomical response remained incomplete — he was, in short, an incomplete responder.

Continuing to inject an eye that is not meaningfully responding is not benign: it carries cost, risk and burden without proportionate benefit. Photodynamic therapy with verteporfin may have been the more rational next step for this pachychoroid-driven process — but that option is expensive and, in much of the world, simply inaccessible.

A patient with sub-retinal fluid had already received intravitreal injections elsewhere, on the assumption that the fluid represented neovascular activity. The diagnosis, however, was adult-onset vitelliform dystrophy — a degenerative accumulation of material, not an exudative membrane.

Crucially, there was no neovascular network on OCT-angiography or fluorescein angiography. In the absence of a network, the fluid here is not a target for anti-VEGF therapy. Injections were discontinued and the patient placed on structural OCT surveillance.

A woman with central serous chorioretinopathy was managed with oral eplerenone rather than intravitreal therapy. Across serial imaging the sub-retinal fluid resolved and vision improved from 6/12 to 6/9 — an injection avoided altogether. Throughout, OCT-angiography showed no neovascular network, confirming there was nothing to inject against.

Central serous chorioretinopathy is frequently self-limiting, and where treatment is warranted the choice of route matters. A well-selected systemic option can achieve resolution while sparing the eye an unnecessary intraocular procedure.

An eye that read as unremarkable on routine clinical examination and structural OCT was studied further on OCT-angiography, which revealed a neovascular network that would otherwise have been dismissed. Recognising it changed the plan entirely.

Rather than reassure and discharge, the patient was warned, given an Amsler grid for self-monitoring, and placed on closer follow-up — so that if the membrane activates, treatment can begin without delay.

An eye presented with a sudden central black spot and a dense pre-macular (sub-internal-limiting-membrane) haemorrhage — the picture of a Valsalva-type bleed. Intervention had been considered elsewhere.

The evidence favoured patience. Managed by observation alone, the haemorrhage cleared spontaneously and vision recovered — without a laser and without an operation.

A woman with hypertension and a history of transient ischaemic attacks presented with visual loss from hypertensive retinopathy involving the macula. Rather than defaulting to an intraocular intervention, the priority was to optimise her systemic status — managed medically, in concert with her physicians.

Vision improved from 6/18 partial to 6/6 partial at one month. The retina here was a window onto a systemic vascular problem; controlling the underlying condition reversed the ocular picture.

Two young men presented with trauma, and were managed very differently. A 22-year-old with a firecracker injury had a small submacular haemorrhage with relatively preserved vision; he was managed by observation, allowing the small bleed to resorb.

A 15-year-old struck by a cricket ball had a large submacular haemorrhage with choroidal rupture and a significant drop in vision. Here observation was not enough: he underwent intravitreal SF6 gas to displace the submacular blood.

Restraint is not the same as reluctance. A 78-year-old man with macular neovascularisation from age-related macular degeneration and two months of declining vision in the left eye needed exactly what the earlier cases did not: timely, regular intravitreal anti-VEGF therapy, monitored with serial fundus photography and OCT.

With sustained, disciplined treatment, functional vision was regained and preserved. The judgement here was recognising genuine exudative disease and committing to the long-term follow-up that neovascular AMD demands.